Related Experiment Video
Updated: May 24, 2026

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
Published on: February 14, 2012
New dopamine agonist pramipexole improves parkinsonism and depression in Parkinson's disease
Toshihide Harada1, Fumiko Ishizaki, Nobuko Horie
1Faculty of Health and Welfare, Prefectural University of Hiroshima, 1-1, Gakuen-machi, Mihara, Hiroshima 723-0053, Japan. hartoshi@pu-hiroshima.ac.jp
Abstract:
Previous studies have shown that pramipexole might have the potential to improve depressive symptoms in patients with Parkinson's disease. To provide more evidence, in five Japanese patients at Hoehn & Yahr stage 1-3 we evaluated the Unified Parkinson's Disease Rating Scale (UPDRS), Hamilton Depression Rating Scale (HAMD) and Montgomery Asberg Depression Rating Scale (MADRS) at our hospital. After the pramipexole treatment, each total score of UPDRS, HAMD and MADRS significantly decreased compared with that before the treatment. Our data indicate that pramipexole improves depressive symptoms in patients with Parkinson's disease.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview
Antidepressant Drugs: MAOIs and Other Agents
Parkinson Disease ll: Pathophysiology
Parkinson Disease l: Introduction
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists